

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number  
WO 02/06453 A2

(51) International Patent Classification<sup>7</sup>: C12N 9/00

(21) International Application Number: PCT/EP01/07859

(22) International Filing Date: 9 July 2001 (09.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/218,832 18 July 2000 (18.07.2000) US

(71) Applicant (for all designated States except US): BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): RAMAKRISHNAN, Shyam [IN/US]; Apartment #10, 76 Euston Road, Brighton, MA 02135 (US).

(74) Common Representative: BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report
- entirely in electronic form (except for this front page) and available upon request from the International Bureau
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/06453 A2

(54) Title: REGULATION OF HUMAN DESC1-LIKE SERINE PROTEASE

(57) Abstract: Reagents which regulate human DESC1-like serine protease and reagents which bind to human DESC1-like serine protease gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to cancer, chronic obstructive pulmonary disease (COPD), cardiovascular, and peripheral or central nervous system disease.

**REGULATION OF HUMAN DESC1-LIKE SERINE PROTEASE****TECHNICAL FIELD OF THE INVENTION**

5 The invention relates to the regulation of human DESC1-like serine protease.

**BACKGROUND OF THE INVENTION**

10 Proteases hydrolyze the peptide bond between amino acids and play critical roles in metabolism and other biological processes. They regulate enzymatic activity by processing enzyme precursors into functional enzymes, release enzymes extracellularly, and proteolytically activate enzymes. Differential expression or otherwise selective activation of proteases has been implicated in disease states. Numerous human diseases have been correlated with protease level. For a brief review, see US  
15 Patent No. 6,001,814. For example, HIV proteins are translated as a polyprotein precursor which are inactive until released as mature molecules by an HIV encoded protease. Therefore, identification of proteases and protease agonists and antagonists are important in medicine.

20 One class of proteases is the serine protease. The serine protease class is made up of a variety of proteases, to include elastase, chymotrypsin, cathepsin G, trypsin and thrombin. The serine proteases are characterized by a catalytic triad consisting of serine-195, histidine-57 and aspartic acid-102 (based on the chymotrypsin numbering system). Lang and Schuller deposited a sequence in the EMBL data base, EMBL  
25 Accession No. AF064819, which is described as a cDNA sequence of a gene differently expressed in squamous cell carcinoma, DESC1. DESC1 is a serine protease. DESC1 is expressed in normal oral epithelium, but not in squamous cell tongue carcinoma or metastatic neck nodal tissue.

- 2 -

This implicates a role for this and similar genes in the disease state. A need exists for isolation of related genes and identification of agonists and antagonists of those genes and their respective gene products.

5      **SUMMARY OF THE INVENTION**

It is an object of the invention to provide reagents and methods of regulating a human DESC1-like serine protease. This and other objects of the invention are provided by one or more of the embodiments described below.

10

One embodiment of the invention is a DESC1-like serine protease polypeptide comprising an amino acid sequence selected from the group consisting of:

15      amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 2; and

the amino acid sequence shown in SEQ ID NO: 2.

20      Yet another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a DESC1-like serine protease polypeptide comprising an amino acid sequence selected from the group consisting of:

25      amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 2; and

the amino acid sequence shown in SEQ ID NO: 2.

30      Binding between the test compound and the DESC1-like serine protease polypeptide is detected. A test compound which binds to the DESC1-like serine protease polypeptide is thereby identified as a potential agent for decreasing extracellular

matrix degradation. The agent can work by decreasing the activity of the DESC1-like serine protease.

5 Another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a polynucleotide encoding a DESC1-like serine protease polypeptide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

10 nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 6; and

the nucleotide sequence shown in SEQ ID NO: 6.

15 Binding of the test compound to the polynucleotide is detected. A test compound which binds to the polynucleotide is identified as a potential agent for decreasing extracellular matrix degradation. The agent can work by decreasing the amount of the DESC1-like serine protease through interacting with the DESC1-like serine protease mRNA.

20 Another embodiment of the invention is a method of screening for agents which regulate extracellular matrix degradation. A test compound is contacted with a DESC1-like serine protease polypeptide comprising an amino acid sequence selected from the group consisting of:

25 amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 2; and

the amino acid sequence shown in SEQ ID NO: 2.

30 A DESC1-like serine protease activity of the polypeptide is detected. A test compound which increases DESC1-like serine protease activity of the polypeptide

relative to DESC1-like serine protease activity in the absence of the test compound is thereby identified as a potential agent for increasing extracellular matrix degradation.

5 A test compound which decreases DESC1-like serine protease activity of the polypeptide relative to DESC1-like serine protease activity in the absence of the test compound is thereby identified as a potential agent for decreasing extracellular matrix degradation.

10 Even another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation. A test compound is contacted with a DESC1-like serine protease product of a polynucleotide which comprises a nucleotide sequence selected from the group consisting of:

15 nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 6; and

the nucleotide sequence shown in SEQ ID NO: 6.

20 Binding of the test compound to the DESC1-like serine protease product is detected. A test compound which binds to the DESC1-like serine protease product is thereby identified as a potential agent for decreasing extracellular matrix degradation.

25 Still another embodiment of the invention is a method of reducing extracellular matrix degradation. A cell is contacted with a reagent which specifically binds to a polynucleotide encoding a DESC1-like serine protease polypeptide or the product encoded by the polynucleotide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of:

30 nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 6; and

the nucleotide sequence shown in SEQ ID NO: 6.

DESC1-like serine protease activity in the cell is thereby decreased.

5 The invention thus provides a human DESC1-like serine protease which can be used to identify test compounds which may act, for example, as agonists or antagonists at the enzyme's active site. Human DESC1-like serine protease and fragments thereof also are useful in raising specific antibodies which can block the enzyme and effectively reduce its activity.

10

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the DNA-sequence of the protein identified with EMBL Accesssion No. AF064819 (SEQ ID NO:1).

15 Fig. 2 shows the amino acid sequence of a DESC1-like serine protease polypeptide (SEQ ID NO:2).

Fig. 3 shows the amino acid sequence of the protein identified with EMBL Accesssion No. AF064819 (SEQ ID NO:3).

20 Fig. 4 shows the amino acid sequence of a consensus hidden Marcov Model sequence (SEQ ID NO:4).

Fig. 5 shows the DNA-sequence of an EST, EMBL Accesssion No. U77054 (SEQ ID NO: 5).

Fig. 6 shows the DNA-sequence of a DESC1-like serine protease polypeptide (SEQ ID NO: 6).

25 Fig. 7 shows the BLASTP alignment of DESC1-like serine protease polypeptide (SEQ ID NO:2) designated as the query (Q) sequence with the protein identified with EMBL Accesssion No. AF064819 (SEQ ID NO: 3) designated as the homolog (H). The sequences shown in bold were identified by a PROSITE data base search. The underlined sequences were identified by a BLOCKS data base search.

30

Fig. 8 shows the results of a PROSITE data base search on the amino acid sequence of SEQ ID NO:2.

Fig. 9 shows the results of a BLOCKS data base search on the amino acid sequence of SEQ ID NO:2.

5 Fig. 10 shows the HMMPFAM alignment between the indicated portion of SEQ ID NO:2 and a consensus hidden Marcov Model sequence (SEQ ID NO:4).

#### DETAILED DESCRIPTION OF THE INVENTION

10 The invention relates to an isolated polynucleotide encoding a DESC1-like serine protease polypeptide and being selected from the group consisting of:

a) a polynucleotide encoding a DESC1-like serine protease polypeptide comprising an amino acid sequence selected from the group consisting of:

15 amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 2; and the amino acid sequence shown in SEQ ID NO: 2.

b) a polynucleotide comprising the sequence of SEQ ID NO: 6;

c) a polynucleotide which hybridizes under stringent conditions to a 20 polynucleotide specified in (a) and (b);

d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code; and

e) a polynucleotide which represents a fragment, derivative or allelic variation of 25 a polynucleotide sequence specified in (a) to (d).

Furthermore, it has been discovered by the present applicant that a novel DESC1-like serine protease, particularly a human DESC1-like serine protease, is a discovery of the present invention. Human DESC1-like serine protease comprises the amino acid sequence shown in SEQ ID NO:2. Human DESC1-like serine protease was identified 5 by searching human sequences with serine protease DESC1 (SEQ ID NO:3, EMBL Accession No. AF064819). A coding sequence for human DESC1-like serine protease (SEQ ID NO:6) is found in the human clone identified with GenBank Accession Nos. AC013642 and AC012571; additional 3' sequences are shown in SEQ ID NO:1. Human DESC1-like serine protease gene is located on human chromosome 10 15.

Human DESC1-like serine protease is 46% identical over 313 amino acids to the protein identified with EMBL Accession No. AF064819 and annotated as a serine protease DESC1 (FIG. 1). Human DESC1-like serine protease as shown in SEQ ID NO:2 contains 322 amino acids. The domains indicated in Figures 2 and 3, SEQ ID NOS: 6-15, identify the enzyme of the invention as a trypsin-his serine protease and indicate functional roles for the protein. For example, the fibronectin domain suggests the DESC1-like serine protease to be a cell surface protein. See BLOCKS Nos. BL01253H and BL01253G in Fig. 3 and also BIOCHEMISTRY, 3rd edition, L. 15 Stryer editor, at page 127, Freeman and Company Press (1988). Other blocks are serine protease typical blocks and include the Kringle domain and the Apple domain protein blocks. Figure 4 further underscores the identification of this serine protease 20 as part of the trypsin family by showing a high degree of identity between the indicated portion of the DESC1-like serine protease and a Marco model trypsin 25 consensus protein sequence (SEQ ID NO: 4).

The human DESC1-like serine protease coding sequence is expressed, as indicated by a nearly perfect alignment between a portion of the coding region of the DESC1-like serine protease spanning the TAA stop codon and the sequence of an EST, EMBL 30 Accession No. U77054, SEQ ID NO:5. The EST is described as having a role in primary cancers.

5 The human DESC1-like serine protease of the invention is expected to be useful for treatments and diagnostics of cancer, chronic obstructive pulmonary disease (COPD), cardiovascular and peripheral or central nervous system disease. Human DESC1-like serine protease and gene can also be used to screen for human DESC1-like serine protease and gene agonists and antagonists.

Polypeptides

10 DESC1-like serine protease polypeptides according to the invention comprise at least 14, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 175, 200, 250, or 300 contiguous amino acids selected from the amino acid sequence shown in SEQ ID NO:2 or a biologically active variant thereof, as defined below. A DESC1-like serine protease polypeptide of the invention therefore can be a portion of a DESC1-like serine protease protein, a full-length DESC1-like serine protease protein, or a fusion protein comprising all or a portion of a DESC1-like serine protease protein.

15

Biologically Active Variants

20 DESC1-like serine protease polypeptide variants which are biologically active, i.e., retain a serine protease, and, preferably, a trypsin serine protease activity, also are DESC1-like serine protease polypeptides. Preferably, naturally or non-naturally occurring DESC1-like serine protease polypeptide variants have amino acid sequences which are at least about 47, 50, 55, 60, 65, or 70, preferably about 75, 80, 85, 90, 96, 97, or 98% identical to the amino acid sequence shown in SEQ ID NO:2 or a fragment thereof. Percent identity between a putative DESC1-like serine protease polypeptide variant and an amino acid sequence of SEQ ID NO:2 is determined using Blast2 alignment program (Blosum62, Expect 10, standard genetic codes).

25

30 Variations in percent identity can be due, for example, to amino acid substitutions, insertions, or deletions. Amino acid substitutions are defined as one for one amino

acid replacements. They are conservative in nature when the substituted amino acid has similar structural and/or chemical properties. Examples of conservative replacements are substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

5

Amino acid insertions or deletions are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity of a DESC1-like serine protease polypeptide can 10 be found using computer programs well known in the art, such as DNASTAR software. Whether an amino acid change results in a biologically active DESC1-like serine protease polypeptide can readily be determined by assaying for serine protease activity as described, for example, in U.S. Patents 5,595,948, 5,840,510 and 6,001,814.

15

Fusion Proteins

Fusion proteins are useful for generating antibodies against DESC1-like serine protease polypeptide amino acid sequences and for use in various assay systems. For 20 example, fusion proteins can be used to identify proteins which interact with portions of a DESC1-like serine protease polypeptide. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.

25

A DESC1-like serine protease polypeptide fusion protein comprises two polypeptide segments fused together by means of a peptide bond. The first polypeptide segment comprises at least 14, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 175, 200, 250, or 300 contiguous amino acids of SEQ ID NO:2 or of a biologically active variant, 30 such as those described above. The first polypeptide segment also can comprise full-length DESC1-like serine protease protein.

The second polypeptide segment can be a full-length protein or a protein fragment. Proteins commonly used in fusion protein construction include  $\beta$ -galactosidase,  $\beta$ -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including 5 blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). Additionally, epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding 10 protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. A fusion protein also can be engineered to contain a cleavage site located between the DESC1-like serine protease polypeptide-encoding sequence and the heterologous protein sequence, so that the DESC1-like serine protease polypeptide can be cleaved 15 and purified away from the heterologous moiety.

A fusion protein can be synthesized chemically, as is known in the art. Preferably, a fusion protein is produced by covalently linking two polypeptide segments or by standard procedures in the art of molecular biology. Recombinant DNA methods can 20 be used to prepare fusion proteins, for example, by making a DNA construct which comprises coding sequences selected from SEQ ID NO:6 in proper reading frame with nucleotides encoding the second polypeptide segment and expressing the DNA construct in a host cell, as is known in the art. Many kits for constructing fusion proteins are available from companies such as Promega Corporation (Madison, WI), Stratagene (La Jolla, CA), CLONTECH (Mountain View, CA), Santa Cruz 25 Biotechnology (Santa Cruz, CA), MBL International Corporation (MIC; Watertown, MA), and Quantum Biotechnologies (Montreal, Canada; 1-888-DNA-KITS).

Identification of Species Homologs

Species homologs of human DESC1-like serine protease polypeptide can be obtained  
5 using DESC1-like serine protease polypeptide polynucleotides (described below) to make suitable probes or primers for screening cDNA expression libraries from other species, such as mice, monkeys, or yeast, identifying cDNAs which encode homologs of DESC1-like serine protease polypeptide, and expressing the cDNAs as is known in the art.

10

Polynucleotides

A DESC1-like serine protease polynucleotide can be single- or double-stranded and comprises a coding sequence or the complement of a coding sequence for a DESC1-like serine protease polypeptide. A coding sequence for human DESC1-like serine protease is shown in SEQ ID NO:6.

Degenerate nucleotide sequences encoding human DESC1-like serine protease polypeptides, as well as homologous nucleotide sequences which are at least about 50, 20 preferably about 75, 90, 96, or 98% identical to the nucleotide sequence shown in SEQ ID NO:1 also are DESC1-like serine protease polynucleotides. Percent sequence identity between the sequences of two polynucleotides is determined using computer programs such as ALIGN which employ the FASTA algorithm, using an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2. 25 Complementary DNA (cDNA) molecules, species homologs, and variants of DESC1-like serine protease polynucleotides which encode biologically active DESC1-like serine protease polypeptides also are DESC1-like serine protease polynucleotides.

Identification of Polynucleotide Variants and Homologs

Variants and homologs of the DESC1-like serine protease polynucleotides described above also are DESC1-like serine protease polynucleotides. Typically, homologous 5 DESC1-like serine protease polynucleotide sequences can be identified by hybridization of candidate polynucleotides to known DESC1-like serine protease polynucleotides under stringent conditions, as is known in the art. For example, using the following wash conditions—2X SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2X SSC, 0.1% SDS, 50 °C 10 once, 30 minutes; then 2X SSC, room temperature twice, 10 minutes each—homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.

15 Species homologs of the DESC1-like serine protease polynucleotides disclosed herein also can be identified by making suitable probes or primers and screening cDNA expression libraries from other species, such as mice, monkeys, or yeast. Human variants of DESC1-like serine protease polynucleotides can be identified, for example, by screening human cDNA expression libraries. It is well known that the  $T_m$  of a 20 double-stranded DNA decreases by 1-1.5 °C with every 1% decrease in homology (Bonner *et al.*, *J. Mol. Biol.* 81, 123 (1973)). Variants of human DESC1-like serine protease polynucleotides or DESC1-like serine protease polynucleotides of other species can therefore be identified by hybridizing a putative homologous DESC1-like 25 serine protease polynucleotide with a polynucleotide having a nucleotide sequence of SEQ ID NO:1 or the complement thereof to form a test hybrid. The melting temperature of the test hybrid is compared with the melting temperature of a hybrid comprising polynucleotides having perfectly complementary nucleotide sequences, and the number or percent of basepair mismatches within the test hybrid is calculated.

30 Nucleotide sequences which hybridize to DESC1-like serine protease polynucleotides or their complements following stringent hybridization and/or wash conditions also

are DESC1-like serine protease polynucleotides. Stringent wash conditions are well known and understood in the art and are disclosed, for example, in Sambrook *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, 2d ed., 1989, at pages 9.50-9.51.

5      Typically, for stringent hybridization conditions a combination of temperature and salt concentration should be chosen that is approximately 12-20 °C below the calculated  $T_m$  of the hybrid under study. The  $T_m$  of a hybrid between a DESC1-like serine protease polynucleotide having a nucleotide sequence shown in SEQ ID NO:1 or 6 or the complement thereof and a polynucleotide sequence which is at least about 50, 55, 10     60, 65, 70 preferably about 75, 90, 96, or 98% identical to one of those nucleotide sequences can be calculated, for example, using the equation of Bolton and McCarthy, *Proc. Natl. Acad. Sci. U.S.A.* 48, 1390 (1962):

15      $T_m = 81.5 \text{ } ^\circ\text{C} - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G + C) - 0.63(\%\text{formamide}) - 600/l$ ,  
where  $l$  = the length of the hybrid in basepairs.

20     Stringent wash conditions include, for example, 4X SSC at 65 °C, or 50% formamide, 4X SSC at 42 °C, or 0.5X SSC, 0.1% SDS at 65 °C. Highly stringent wash conditions include, for example, 0.2X SSC at 65 °C.

25     Preparation of Polynucleotides

A naturally occurring DESC1-like serine protease polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids. 25     Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated DESC1-like serine protease 30     polynucleotides. For example, restriction enzymes and probes can be used to isolate polynucleotide fragments which comprises DESC1-like serine protease nucleotide

sequences. Isolated polynucleotides are in preparations which are free or at least 70, 80, or 90% free of other molecules.

DESC1-like serine protease cDNA molecules can be made with standard molecular  
5 biology techniques, using DESC1-like serine protease mRNA as a template. DESC1-like serine protease cDNA molecules can thereafter be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook *et al.* (1989). An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or  
10 cDNA as a template.

Alternatively, synthetic chemistry techniques can be used to synthesize DESC1-like serine protease polynucleotides. The degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode a DESC1-like serine protease polypeptide having, for example, an amino acid sequence shown in SEQ ID  
15 NO:2 or a biologically active variant thereof.

Extending Polynucleotides

20 Various PCR-based methods can be used to extend the nucleic acid sequences disclosed herein to detect upstream sequences such as promoters and regulatory elements. For example, restriction-site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, *PCR Methods Appl.* 2, 318-322, 1993). Genomic DNA is first amplified in the presence of a primer to a  
25 linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

30 Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region (Triglia *et al.*, *Nucleic Acids Res.* 16, 8186, 1988). Primers

can be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72 °C. The method uses several restriction enzymes 5 to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which can be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial 10 chromosome DNA (Lagerstrom *et al.*, *PCR Methods Applic.* 1, 111-119, 1991). In this method, multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

15 Another method which can be used to retrieve unknown sequences is that of Parker *et al.*, *Nucleic Acids Res.* 19, 3055-3060, 1991). Additionally, PCR, nested primers, and PROMOTERFINDER libraries (CLONTECH, Palo Alto, Calif.) can be used to walk genomic DNA (CLONTECH, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

20 When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo 25 d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.

30 Commercially available capillary electrophoresis systems can be used to analyze the size or confirm the nucleotide sequence of PCR or sequencing products. For example, capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and

5 detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity can be converted to electrical signal using appropriate software (e.g. GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display can be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

*Obtaining Polypeptides*

10

DESC1-like serine protease polypeptides can be obtained, for example, by purification from human cells, by expression of DESC1-like serine protease polynucleotides, or by direct chemical synthesis.

15

*Protein Purification*

20

DESC1-like serine protease polypeptides can be purified from any cell which expresses the enzyme, including host cells which have been transfected with DESC1-like serine protease expression constructs. Human normal epithelial cells and primary cancer cells provide an especially useful source of serine protease DESC1 25 DESC1-like serine protease polypeptides. A purified DESC1-like serine protease polypeptide is separated from other compounds which normally associate with the DESC1-like serine protease polypeptide in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis. A preparation of purified DESC1-like serine protease polypeptides is at least 80% pure; preferably, the preparations are 90%, 95%, or 99% pure. Purity of the preparations can be assessed by any means known in the art, such 30 as SDS-polyacrylamide gel electrophoresis.

Expression of Polynucleotides

To express a DESC1-like serine protease polynucleotide, the polynucleotide can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding DESC1-like serine protease polypeptides and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Such techniques are described, for example, in Sambrook *et al.* (1989) and in Ausubel *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1989.

A variety of expression vector/host systems can be utilized to contain and express sequences encoding a DESC1-like serine protease polypeptide. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus expression vectors (e.g., baculovirus), plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids), or animal cell systems.

The control elements or regulatory sequences are those non-translated regions of the vector — enhancers, promoters, 5' and 3' untranslated regions — which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORT1 plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be

used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO, and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) can be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable.

5 If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding a DESC1-like serine protease polypeptide, vectors based on SV40 or EBV can be used with an appropriate selectable marker.

*Bacterial and Yeast Expression Systems*

10

In bacterial systems, a number of expression vectors can be selected depending upon the use intended for the DESC1-like serine protease polypeptide. For example, when a large quantity of a DESC1-like serine protease polypeptide is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene). In a BLUESCRIPT vector, a sequence encoding the DESC1-like serine protease polypeptide can be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced. pIN vectors (Van Heeke & Schuster, *J. Biol. Chem.* 264, 5503-5509, 1989) or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

30 In the yeast *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH can be used. For

- 19 -

reviews, see Ausubel *et al.* (1989) and Grant *et al.*, *Methods Enzymol.* 153, 516-544, 1987.

Plant and Insect Expression Systems

5 If plant expression vectors are used, the expression of sequences encoding DESC1-like serine protease polypeptides can be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV (Takamatsu, *EMBO J.* 6, 307-311, 1987). Alternatively, plant promoters such as the small subunit 10 of RUBISCO or heat shock promoters can be used (Coruzzi *et al.*, *EMBO J.* 3, 1671-1680, 1984; Broglie *et al.*, *Science* 224, 838-843, 1984; Winter *et al.*, *Results Probl. Cell Differ.* 17, 85-105, 1991). These constructs can be introduced into plant 15 cells by direct DNA transformation or by pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (e.g., Hobbs or Murray, in *McGRAW HILL YEARBOOK OF SCIENCE AND TECHNOLOGY*, McGraw Hill, New York, N.Y., pp. 191-196, 1992).

An insect system also can be used to express a DESC1-like serine protease 20 polypeptide. For example, in one such system *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. Sequences encoding DESC1-like serine protease polypeptides can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. 25 Successful insertion of DESC1-like serine protease polypeptides will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which DESC1-like serine protease polypeptides can be expressed (Engelhard *et al.*, *Proc. Nat. Acad. Sci.* 91, 3224-3227, 1994).

Mammalian Expression Systems

A number of viral-based expression systems can be used to express DESC1-like serine protease polypeptides in mammalian host cells. For example, if an adenovirus is used 5 as an expression vector, sequences encoding DESC1-like serine protease polypeptides can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus which is capable of expressing a DESC1-like serine protease polypeptide in infected host cells (Logan & Shenk, 10 *Proc. Natl. Acad. Sci. 81*, 3655-3659, 1984). If desired, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) also can be used to deliver larger fragments of 15 DNA than can be contained and expressed in a plasmid. HACs of 6M to 10M are constructed and delivered to cells via conventional delivery methods (e.g., liposomes, polycationic amino polymers, or vesicles).

Specific initiation signals also can be used to achieve more efficient translation of 20 sequences encoding DESC1-like serine protease polypeptides. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding a DESC1-like serine protease polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases 25 where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by 30 the inclusion of enhancers which are appropriate for the particular cell system which is used (see Scharf *et al.*, *Results Probl. Cell Differ.* 20, 125-162, 1994).

Host Cells

A host cell strain can be chosen for its ability to modulate the expression of the 5 inserted sequences or to process the expressed DESC1-like serine protease polypeptide in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or 10 function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.

15 Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines which stably express DESC1-like serine protease polypeptides can be transformed using expression vectors which can contain viral 20 origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer 25 resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced DESC1-like serine protease sequences. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. See, for example, *ANIMAL CELL CULTURE*, R.I. Freshney, ed., 1986.

Any number of selection systems can be used to recover transformed cell lines.

These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler *et al.*, *Cell* 11, 223-32, 1977) and adenine phosphoribosyltransferase (Lowy *et al.*, *Cell* 22, 817-23, 1980) genes which can be employed in *tk* or *aprl* cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as 5 the basis for selection. For example, *dhfr* confers resistance to methotrexate (Wigler *et al.*, *Proc. Natl. Acad. Sci.* 77, 3567-70, 1980), *npt* confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin *et al.*, *J. Mol. Biol.* 150, 1-14, 1981), and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murray, 1992, *supra*). Additional selectable genes 10 have been described. For example, *trpB* allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, *Proc. Natl. Acad. Sci.* 85, 8047-51, 1988). Visible markers such as anthocyanins, -glucuronidase and its substrate GUS, and luciferase and its 15 substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes *et al.*, *Methods Mol. Biol.* 55, 121-131, 1995).

Detecting Expression

20 Although the presence of marker gene expression suggests that the DESC1-like serine protease polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding a DESC1-like serine protease polypeptide is inserted within a marker gene sequence, in response to induction or selection usually indicates expression of the DESC1-like serine protease 25 polynucleotide.

30 Alternatively, host cells which contain a DESC1-like serine protease polynucleotide and which express a DESC1-like serine protease polypeptide can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based

technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a polynucleotide sequence encoding a DESC1-like serine protease polypeptide can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding a DESC1-like serine protease polypeptide. Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding a DESC1-like serine protease polypeptide to detect transformants which contain a DESC1-like serine protease polynucleotide.

5

10 A variety of protocols for detecting and measuring the expression of a DESC1-like serine protease polypeptide, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on a DESC1-like serine protease polypeptide can be used, or a competitive binding assay can be employed. These and other assays are described in Hampton *et al.*, SEROLOGICAL METHODS: A LABORATORY MANUAL, APS Press, St. Paul, Minn., 1990) and Maddox *et al.*, *J. Exp. Med.* 158, 1211-1216, 1983).

15

20 A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding DESC1-like serine protease polypeptides include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences encoding a DESC1-like serine protease polypeptide can be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes *in vitro* by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and

25

30

US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

5

Expression and Purification of Polypeptides

Host cells transformed with nucleotide sequences encoding a DESC1-like serine protease polypeptide can be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode DESC1-like serine protease polypeptides can be designed to contain signal sequences which direct secretion of soluble DESC1-like serine protease polypeptides through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound DESC1-like serine protease polypeptide.

As discussed above, other constructions can be used to join a sequence encoding a DESC1-like serine protease polypeptide to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAQS extension/affinity purification system (Immunex Corp., Seattle, Wash.). Inclusion of cleavable linker sequences such as those specific for Factor Xa or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the DESC1-like serine protease polypeptide also can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a DESC1-like serine protease polypeptide and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine

residues facilitate purification by IMAC (immobilized metal ion affinity chromatography, as described in P. Rath *et al.*, *Prot. Exp. Purif.* 3, 263-281, 1992), while the enterokinase cleavage site provides a means for purifying the DESC1-like serine protease polypeptide from the fusion protein. Vectors which contain fusion 5 proteins are disclosed in Kroll *et al.*, *DNA Cell Biol.* 12, 441-453, 1993.

Chemical Synthesis

Sequences encoding a DESC1-like serine protease polypeptide can be synthesized, in 10 whole or in part, using chemical methods well known in the art (see Caruthers *et al.*, *Nucl. Acids Res. Symp. Ser.* 215-223, 1980; Horn *et al.* *Nucl. Acids Res. Symp. Ser.* 225-232, 1980). Alternatively, a DESC1-like serine protease polypeptide itself can 15 be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques (Merrifield, *J. Am. Chem. Soc.* 85, 2149-2154, 1963; Roberge *et al.*, *Science* 269, 202-204, 1995). Protein synthesis can be performed using manual techniques or by automation. Automated synthesis 20 can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Optionally, fragments of DESC1-like serine protease polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule.

The newly synthesized peptide can be substantially purified by preparative high 25 performance liquid chromatography (e.g., Creighton, *PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES*, WH Freeman and Co., New York, N.Y., 1983). The composition of a synthetic DESC1-like serine protease polypeptide can be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; *see* Creighton, *supra*). Additionally, any portion of the amino acid sequence of the DESC1-like serine protease polypeptide can be altered during direct synthesis and/or 30 combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.

Production of Altered Polypeptides

As will be understood by those of skill in the art, it may be advantageous to produce DESC1-like serine protease polypeptide-encoding nucleotide sequences possessing 5 non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

10

The nucleotide sequences disclosed herein can be engineered using methods generally known in the art to alter DESC1-like serine protease polypeptide-encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product. DNA 15 shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences. For example, site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

20

Antibodies

Any type of antibody known in the art can be generated to bind specifically to an epitope of a DESC1-like serine protease polypeptide. "Antibody" as used herein 25 includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv, which are capable of binding an epitope of a DESC1-like serine protease polypeptide. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require more, e.g., at least 15, 25, or 50 amino acids.

30

An antibody which specifically binds to an epitope of a DESC1-like serine protease polypeptide can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art. Various immunoassays can be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the immunogen.

10

Typically, an antibody which specifically binds to a DESC1-like serine protease polypeptide provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay. Preferably, antibodies which specifically bind to DESC1-like serine protease polypeptides do not detect other proteins in immunochemical assays and can immunoprecipitate a DESC1-like serine protease polypeptide from solution.

DESC1-like serine protease polypeptides can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies. If desired, a DESC1-like serine protease polypeptide can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin. Depending on the host species, various adjuvants can be used to increase the immunological response. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (e.g., aluminum hydroxide), and surface active substances (e.g. lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol). Among adjuvants used in humans, BCG (*bacilli Calmette-Guerin*) and *Corynebacterium parvum* are especially useful.

Monoclonal antibodies which specifically bind to a DESC1-like serine protease polypeptide can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but

are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler *et al.*, *Nature* 256, 495-497, 1985; Kozbor *et al.*, *J. Immunol. Methods* 81, 31-42, 1985; Cote *et al.*, *Proc. Natl. Acad. Sci.* 80, 2026-2030, 1983; Cole *et al.*, *Mol. Cell Biol.* 62, 109-120, 1984).

5

In addition, techniques developed for the production of "chimeric antibodies," the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison *et al.*, *Proc. Natl. Acad. Sci.* 81, 6851-6855, 1984; Neuberger *et al.*, *Nature* 312, 604-608, 10 1984; Takeda *et al.*, *Nature* 314, 452-454, 1985). Monoclonal and other antibodies also can be "humanized" to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues. Sequence differences between rodent 15 antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grafting of entire complementarity determining regions. Alternatively, humanized antibodies can be produced using recombinant methods, as described in GB2188638B. Antibodies which specifically bind to a DESC1-like serine protease 20 polypeptide can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. 5,565,332.

Alternatively, techniques described for the production of single chain antibodies can be adapted using methods known in the art to produce single chain antibodies which 25 specifically bind to DESC1-like serine protease polypeptides. Antibodies with related specificity, but of distinct idiotypic composition, can be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton, *Proc. Natl. Acad. Sci.* 88, 11120-23, 1991).

30 Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a template (Thirion *et al.*, 1996, *Eur. J.*

*Cancer Prev.* 5, 507-11). Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught, for example, in Coloma & Morrison, 1997, *Nat. Biotechnol.* 15, 159-63. Construction of bivalent, bispecific single-chain antibodies is taught in 5 *Mallender & Voss, 1994, J. Biol. Chem.* 269, 199-206.

A nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant DNA methods, and introduced into a cell to express the coding 10 sequence, as described below. Alternatively, single-chain antibodies can be produced directly using, for example, filamentous phage technology (Verhaar *et al.*, 1995, *Int. J. Cancer* 61, 497-501; Nicholls *et al.*, 1993, *J. Immunol. Meth.* 165, 81-91).

15 Antibodies which specifically bind to DESC1-like serine protease polypeptides also can be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi *et al.*, *Proc. Natl. Acad. Sci.* 86, 3833-3837, 1989; Winter *et al.*, *Nature* 349, 293-299, 1991).

20 Other types of antibodies can be constructed and used therapeutically in methods of the invention. For example, chimeric antibodies can be constructed as disclosed in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.

25 Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which a DESC1-like serine protease polypeptide is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.

30

Antisense Oligonucleotides

Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary 5 nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a 10 cell as described above to decrease the level of DESC1-like serine protease gene products in the cell.

Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an 15 automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamide, carboxymethyl esters, carbonates, and phosphate triesters. See Brown, *Meth. Mol. Biol.* 20, 1-8, 1994; Sonveaux, *Meth. Mol. Biol.* 26, 1-72, 1994; Uhlmann *et al.*, 20 *Chem. Rev.* 90, 543-583, 1990.

Modifications of DESC1-like serine protease gene expression can be obtained by 25 designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of the DESC1-like serine protease gene. Oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition 30 of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons. Therapeutic advances using triplex DNA have been described in the literature (*e.g.*, Gee *et al.*, in Huber & Carr, **MOLECULAR AND**

IMMUNOLOGIC APPROACHES, Futura Publishing Co., Mt. Kisco, N.Y., 1994). An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

5 Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of a DESC1-like serine protease polynucleotide. Antisense oligonucleotides which comprise, for example, 2, 10 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a DESC1-like serine protease polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent DESC1-like serine protease nucleotides, can provide sufficient targeting specificity for DESC1-like serine protease mRNA. Preferably, each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length. Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in 15 length. One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular DESC1-like serine protease polynucleotide sequence.

20 Antisense oligonucleotides can be modified without affecting their ability to hybridize to a DESC1-like serine protease polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule. For example, internucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose. 25 Modified bases and/or sugars, such as arabinose instead of ribose, or a 3', 5'-substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide. These modified oligonucleotides can be prepared by methods well known in the art. See, e.g., Agrawal *et al.*, *Trends Biotechnol.* 10, 152-158, 1992; Uhlmann *et al.*, 30 *Chem. Rev.* 90, 543-584, 1990; Uhlmann *et al.*, *Tetrahedron Lett.* 215, 3539-3542, 1987.

Ribozymes

Ribozymes are RNA molecules with catalytic activity. *See, e.g.*, Cech, *Science* 236, 5 1532-1539; 1987; Cech, *Ann. Rev. Biochem.* 59, 543-568; 1990, Cech, *Curr. Opin. Struct. Biol.* 2, 605-609; 1992, Couture & Stinchcomb, *Trends Genet.* 12, 510-515, 1996. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art (*e.g.*, Haseloff *et al.*, U.S. Patent 5,641,673). The mechanism of 10 ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences.

The coding sequence of a DESC1-like serine protease polynucleotide can be used to 15 generate ribozymes which will specifically bind to mRNA transcribed from the DESC1-like serine protease polynucleotide. Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art (*see* Haseloff *et al.* *Nature* 334, 585-591, 1988). For example, the cleavage activity of ribozymes can be 20 targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme. The hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target (*see, for example*, Gerlach *et al.*, EP 321,201).

25 Specific ribozyme cleavage sites within a DESC1-like serine protease RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural 30 features which may render the target inoperable. Suitability of candidate DESC1-like serine protease RNA targets also can be evaluated by testing accessibility to

hybridization with complementary oligonucleotides using ribonuclease protection assays. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target. The hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.

Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease DESC1-like serine protease expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. A ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells.

As taught in Haseloff *et al.*, U.S. Patent 5,641,673, ribozymes can be engineered so that ribozyme expression will occur in response to factors which induce expression of a target gene. Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.

25 **Screening Methods**

The invention provides assays for screening test compounds which bind to or modulate the activity of a DESC1-like serine protease polypeptide or a DESC1-like serine protease polynucleotide. A test compound preferably binds to a DESC1-like serine protease polypeptide or polynucleotide. More preferably, a test compound decreases or increases DESC1-like serine protease activity by at least about 10,

preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the test compound.

Test Compounds

5

Test compounds can be pharmacologic agents already known in the art or can be compounds previously unknown to have any pharmacological activity. The compounds can be naturally occurring or designed in the laboratory. They can be isolated from microorganisms, animals, or plants, and can be produced recombinantly, 10 or synthesized by chemical methods known in the art. If desired, test compounds can be obtained using any of the numerous combinatorial library methods known in the art, including but not limited to, biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library methods requiring deconvolution, the "one-bead one-compound" library method, and synthetic library 15 methods using affinity chromatography selection. The biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer, or small molecule libraries of compounds. See Lam, *Anticancer Drug Des.* 12, 145, 1997.

20

Methods for the synthesis of molecular libraries are well known in the art (see, for example, DeWitt *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 90, 6909, 1993; Erb *et al.* *Proc. Natl. Acad. Sci. U.S.A.* 91, 11422, 1994; Zuckermann *et al.*, *J. Med. Chem.* 37, 2678, 1994; Cho *et al.*, *Science* 261, 1303, 1993; Carell *et al.*, *Angew. Chem. Int. Ed. Engl.* 33, 2059, 1994; Carell *et al.*, *Angew. Chem. Int. Ed. Engl.* 33, 2061; Gallop *et al.*, *J.*

25

*Med. Chem.* 37, 1233, 1994). Libraries of compounds can be presented in solution (see, e.g., Houghten, *BioTechniques* 13, 412-421, 1992), or on beads (Lam, *Nature* 354, 82-84, 1991), chips (Fodor, *Nature* 364, 555-556, 1993), bacteria or spores (Ladner, U.S. Patent 5,223,409), plasmids (Cull *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89, 1865-1869, 1992), or phage (Scott & Smith, *Science* 249, 386-390, 1990; Devlin, *Science* 249, 404-406, 1990); Cwirla *et al.*, *Proc. Natl. Acad. Sci.* 97, 6378-6382, 1990; Felici, *J. Mol. Biol.* 222, 301-310, 1991; and Ladner, U.S. Patent 5,223,409).

30

High Throughput Screening

Test compounds can be screened for the ability to bind to DESC1-like serine protease polypeptides or polynucleotides or to affect DESC1-like serine protease activity or DESC1-like serine protease gene expression using high throughput screening. Using high throughput screening, many discrete compounds can be tested in parallel so that large numbers of test compounds can be quickly screened. The most widely established techniques utilize 96-well microtiter plates. The wells of the microtiter plates typically require assay volumes that range from 50 to 500  $\mu$ l. In addition to the plates, many instruments, materials, pipettors, robotics, plate washers, and plate readers are commercially available to fit the 96-well format.

Alternatively, "free format assays," or assays that have no physical barrier between samples, can be used. For example, an assay using pigment cells (melanocytes) in a simple homogeneous assay for combinatorial peptide libraries is described by Jayawickreme *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 91, 1614-18 (1994). The cells are placed under agarose in petri dishes, then beads that carry combinatorial compounds are placed on the surface of the agarose. The combinatorial compounds are partially released the compounds from the beads. Active compounds can be visualized as dark pigment areas because, as the compounds diffuse locally into the gel matrix, the active compounds cause the cells to change colors.

Another example of a free format assay is described by Chelsky, "Strategies for Screening Combinatorial Libraries: Novel and Traditional Approaches," reported at the First Annual Conference of The Society for Biomolecular Screening in Philadelphia, Pa. (Nov. 7-10, 1995). Chelsky placed a simple homogenous enzyme assay for carbonic anhydrase inside an agarose gel such that the enzyme in the gel would cause a color change throughout the gel. Thereafter, beads carrying combinatorial compounds via a photolinker were placed inside the gel and the

compounds were partially released by UV-light. Compounds that inhibited the enzyme were observed as local zones of inhibition having less color change.

5 Yet another example is described by Salmon *et al.*, *Molecular Diversity* 2, 57-63 (1996). In this example, combinatorial libraries were screened for compounds that had cytotoxic effects on cancer cells growing in agar.

10 Another high throughput screening method is described in Beutel *et al.*, U.S. Patent 5,976,813. In this method, test samples are placed in a porous matrix. One or more assay components are then placed within, on top of, or at the bottom of a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support. When samples are introduced to the porous matrix they diffuse sufficiently slowly, such that the assays can be performed without the test samples running together.

15 **Binding Assays**

20 For binding assays, the test compound is preferably a small molecule which binds to and occupies, for example, the ATP/GTP binding site of the enzyme or the active site of the DESC1-like serine protease polypeptide, such that normal biological activity is prevented. Examples of such small molecules include, but are not limited to, small peptides or peptide-like molecules.

25 In binding assays, either the test compound or the DESC1-like serine protease polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase. Detection of a test compound which is bound to the DESC1-like serine protease polypeptide can then be accomplished, for example, by direct counting of radioemission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product.

Alternatively, binding of a test compound to a DESC1-like serine protease polypeptide can be determined without labeling either of the interactants. For example, a microphysiometer can be used to detect binding of a test compound with a DESC1-like serine protease polypeptide. A microphysiometer (e.g., Cytosensor<sup>TM</sup>) is 5 an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a test compound and a DESC1-like serine protease polypeptide (McConnell *et al.*, *Science* 257, 1906-1912, 1992).

10

Determining the ability of a test compound to bind to a DESC1-like serine protease polypeptide also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) (Sjolander & Urbaniczky, *Anal. Chem.* 63, 2338-2345, 1991, and Szabo *et al.*, *Curr. Opin. Struct. Biol.* 5, 699-705, 1995). BIA 15 is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIACore<sup>TM</sup>). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

20

In yet another aspect of the invention, a DESC1-like serine protease polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent 5,283,317; Zervos *et al.*, *Cell* 72, 223-232, 1993; Madura *et al.*, *J. Biol. Chem.* 268, 12046-12054, 1993; Bartel *et al.*, *BioTechniques* 14, 920-924, 1993; Iwabuchi *et al.*, *Oncogene* 8, 1693-1696, 1993; and Brent W094/10300), to identify other proteins 25 which bind to or interact with the DESC1-like serine protease polypeptide and modulate its activity.

30

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. For example, in one construct, polynucleotide encoding a DESC1-like serine protease polypeptide can be fused to a polynucleotide

encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct a DNA sequence that encodes an unidentified protein ("prey" or "sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact *in vivo* to form an protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ), which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with the DESC1-like serine protease polypeptide.

It may be desirable to immobilize either the DESC1-like serine protease polypeptide (or polynucleotide) or the test compound to facilitate separation of bound from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay. Thus, either the DESC1-like serine protease polypeptide (or polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art can be used to attach the DESC1-like serine protease polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support. Test compounds are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to a DESC1-like serine protease polypeptide (or polynucleotide) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.

In one embodiment, the DESC1-like serine protease polypeptide is a fusion protein comprising a domain that allows the DESC1-like serine protease polypeptide to be bound to a solid support. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or 5 glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the non-adsorbed DESC1-like serine protease polypeptide; the mixture is then incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components. 10 Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.

Other techniques for immobilizing proteins or polynucleotides on a solid support also 15 can be used in the screening assays of the invention. For example, either a DESC1-like serine protease polypeptide (or polynucleotide) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated DESC1-like serine protease polypeptides (or polynucleotides) or test compounds can be prepared from biotin-NHS(N-hydroxysuccinimide) using techniques well known in 20 the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies which specifically bind to a DESC1-like serine protease polypeptide, polynucleotide, or a test compound, but which do not interfere with a desired binding site, such as the ATP/GTP binding site or the active site of the DESC1-like serine 25 protease polypeptide, can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.

Methods for detecting such complexes, in addition to those described above for the 30 GST-immobilized complexes, include immunodetection of complexes using antibodies which specifically bind to the DESC1-like serine protease polypeptide or test compound, enzyme-linked assays which rely on detecting an activity of the

DESC1-like serine protease polypeptide, and SDS gel electrophoresis under non-reducing conditions.

Screening for test compounds which bind to a DESC1-like serine protease polypeptide or polynucleotide also can be carried out in an intact cell. Any cell which comprises a DESC1-like serine protease polypeptide or polynucleotide can be used in a cell-based assay system. A DESC1-like serine protease polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Binding of the test compound to a DESC1-like serine protease polypeptide or polynucleotide is determined as described above.

Enzyme Assays

Test compounds can be tested for the ability to increase or decrease the serine protease activity of a human DESC1-like serine protease polypeptide. Serine protease activity can be measured, for example, as described in US Patent Nos. 5,695,948, 5,840,510 and 6,001,814.

Enzyme assays can be carried out after contacting either a purified DESC1-like serine protease polypeptide, a cell membrane preparation, or an intact cell with a test compound. A test compound which decreases a transketolase activity of a DESC1-like serine protease polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for decreasing DESC1-like serine protease activity. A test compound which increases a serine protease, preferably a serine protease trypsin activity of a human DESC1-like serine protease polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for increasing human DESC1-like serine protease activity.

Gene Expression

In another embodiment, test compounds which increase or decrease DESC1-like serine protease gene expression are identified. A DESC1-like serine protease 5 polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of the DESC1-like serine protease polynucleotide is determined. The level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of mRNA or polypeptide in the absence of the test compound. The test compound can then be identified as a 10 modulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less in the presence of the test compound than in its absence, the test compound is 15 identified as an inhibitor of the mRNA or polypeptide expression.

The level of DESC1-like serine protease mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA or 20 polypeptide. Either qualitative or quantitative methods can be used. The presence of polypeptide products of a DESC1-like serine protease polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunoochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry. Alternatively, polypeptide synthesis can be determined *in vivo*, in a cell culture, or in an *in vitro* translation system by detecting incorporation of 25 labeled amino acids into a DESC1-like serine protease polypeptide.

Such screening can be carried out either in a cell-free assay system or in an intact cell. Any cell which expresses a DESC1-like serine protease polynucleotide can be used in 30 a cell-based assay system. The DESC1-like serine protease polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those

described above. Either a primary culture or an established cell line, such as CHO or human embryonic kidney 293 cells, can be used.

Pharmaceutical Compositions

5

The invention also provides pharmaceutical compositions which can be administered to a patient to achieve a therapeutic effect. Pharmaceutical compositions of the invention can comprise, for example, a DESC1-like serine protease polypeptide, DESC1-like serine protease polynucleotide, ribozymes or antisense oligonucleotides, 10 antibodies which specifically bind to a DESC1-like serine protease polypeptide, or mimetics, agonists, antagonists, or inhibitors of a DESC1-like serine protease polypeptide activity. The compositions can be administered alone or in combination with at least one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, 15 saline, buffered saline, dextrose, and water. The compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.

20

In addition to the active ingredients, these pharmaceutical compositions can contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Pharmaceutical compositions of the invention can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, 25 subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means. Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

30

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, 5 such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents can be added, such as the cross-linked polyvinyl 10 pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and 15 suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made 20 of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid 25 polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration can be formulated 30 in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally,

suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers also can be used for delivery. Optionally, the 5 suspension also can contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

10 The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. The pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, 15 acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation can be a lyophilized powder which can contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

20 Further details on techniques for formulation and administration can be found in the latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES (Maack Publishing Co., Easton, Pa.). After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition.

25 Such labeling would include amount, frequency, and method of administration.

*Therapeutic Indications and Methods*

30 The DESC1-like serine protease of the invention can be regulated to provide therapeutic effects in diseases such as cancer, chronic obstructive pulmonary disease (COPD), cardiovascular, and peripheral or central nervous system disease. It is

expressed in primary cancer cells, as shown by identification of an EST (EMBL Accession No. U77054, SEQ ID NO: 5) with nearly perfect identity to the 3'-end of the coding region of the DESC1-like serine protease.

5     Cancer is a disease fundamentally caused by oncogenic cellular transformation. There are several hallmarks of transformed cells that distinguish them from their normal counterparts and underlie the pathophysiology of cancer. These include uncontrolled cellular proliferation, unresponsiveness to normal death-inducing signals (immortalization), increased cellular motility and invasiveness, increased ability to  
10    recruit blood supply through induction of new blood vessel formation (angiogenesis), genetic instability, and dysregulated gene expression. Various combinations of these aberrant physiologies, along with the acquisition of drug-resistance frequently lead to an intractable disease state in which organ failure and patient death ultimately ensue.

15    Most standard cancer therapies target cellular proliferation and rely on the differential proliferative capacities between transformed and normal cells for their efficacy. This approach is hindered by the facts that several important normal cell types are also highly proliferative and that cancer cells frequently become resistant to these agents. Thus, the therapeutic indices for traditional anti-cancer therapies rarely exceed 2.0.

20    Genomics-driven molecular target identification has opened up the possibility of identifying new cancer-specific targets for therapeutic intervention that will provide safer, more effective treatments for cancer patients. Thus, newly discovered tumor-associated genes and their products can be tested for their role(s) in disease and  
25    used as tools to discover and develop innovative therapies. Genes playing important roles in any of the physiological processes outlined above can be characterized as cancer targets.

30    The genes can be used as treatments. Alternatively, genes or gene fragments identified through genomics can readily be expressed in one or more heterologous expression systems to produce functional recombinant proteins. These proteins are

characterized *in vitro* for their biochemical properties and then used as tools in high-throughput molecular screening programs to identify chemical modulators of their biochemical activities. Agonists and/or antagonists of target protein activity can be identified in this manner and subsequently tested in cellular and *in vivo* disease 5 models for anti-cancer activity. Optimization of lead compounds with iterative testing in biological models and detailed pharmacokinetic and toxicological analyses form the basis for drug development and subsequent testing in humans.

10 The DESC1-like serine protease gene, the enzyme, or agonist or antagonists thereof can have a therapeutic effect on those cardiovascular conditions. Cardiovascular diseases include the following disorders of the heart and the vascular system: congestive heart failure, myocardial infarction, ischemic diseases of the heart, all kinds of atrial and ventricular arrhythmias, hypertensive vascular diseases and peripheral vascular diseases.

15 Heart failure is defined as a pathophysiologic state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failure such as high-output and low-output, acute and chronic, right-sided or 20 left-sided, systolic or diastolic, independent of the underlying cause.

25 Myocardial infarction (MI) is generally caused by an abrupt decrease in coronary blood flow that follows a thrombotic occlusion of a coronary artery previously narrowed by arteriosclerosis. MI prophylaxis (primary and secondary prevention) is included as well as the acute treatment of MI and the prevention of complications.

Ischemic diseases are conditions in which the coronary flow is restricted resulting in an perfusion which is inadequate to meet the myocardial requirement for oxygen. This group of diseases include stable angina, unstable angina and asymptomatic 30 ischemia.



Arrhythmias include all forms of atrial and ventricular tachyarrhythmias (atrial tachycardia, atrial flutter, atrial fibrillation, atrio-ventricular reentrant tachycardia, pre-excitation syndrome, ventricular tachycardia, ventricular flutter, ventricular fibrillation) as well as bradycardic forms of arrhythmias.

5

Hypertensive vascular diseases include primary as well as all kinds of secondary arterial hypertension (renal, endocrine, neurogenic, others). The genes may be used as drug targets for the treatment of hypertension as well as for the prevention of all complications.

10

Peripheral vascular diseases are defined as vascular diseases in which arterial and/or venous flow is reduced resulting in an imbalance between blood supply and tissue oxygen demand. It includes chronic peripheral arterial occlusive disease (PAOD), acute arterial thrombosis and embolism, inflammatory vascular disorders, Raynaud's phenomenon and venous disorders.

15

CNS disorders, such as Parkinson's disease, corticobasal degeneration, motor neuron disease, dementia, ALS, multiple sclerosis, traumatic brain injury, post-traumatic brain injury, small-vessel cerebrovascular disease, stroke, and post-stroke sequelae also can be treated by regulating human DESC1-like serine protease.

20

This invention further pertains to the use of novel agents identified by the screening assays described above. Accordingly, it is within the scope of this invention to use a test compound identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a modulating agent, an antisense nucleic acid molecule, a specific antibody, ribozyme, or a DESC1-like serine protease polypeptide binding molecule) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of

25

30

novel agents identified by the above-described screening assays for treatments as described herein.

A reagent which affects DESC1-like serine protease activity can be administered to a 5 human cell, either *in vitro* or *in vivo*, to reduce DESC1-like serine protease activity. The reagent preferably binds to an expression product of a human DESC1-like serine protease gene. If the expression product is a protein, the reagent is preferably an antibody. For treatment of human cells *ex vivo*, an antibody can be added to a preparation of stem cells which have been removed from the body. The cells can then 10 be replaced in the same or another human body, with or without clonal propagation, as is known in the art.

In one embodiment, the reagent is delivered using a liposome. Preferably, the 15 liposome is stable in the animal into which it has been administered for at least about 30 minutes, more preferably for at least about 1 hour, and even more preferably for at least about 24 hours. A liposome comprises a lipid composition that is capable of targeting a reagent, particularly a polynucleotide, to a particular site in an animal, such as a human. Preferably, the lipid composition of the liposome is capable of targeting to a specific organ of an animal, such as the lung, liver, spleen, heart brain, lymph 20 nodes, and skin.

A liposome useful in the present invention comprises a lipid composition that is capable of fusing with the plasma membrane of the targeted cell to deliver its contents to the cell. Preferably, the transfection efficiency of a liposome is about 0.5 g of 25 DNA per 16 nmole of liposome delivered to about  $10^6$  cells, more preferably about 1.0 g of DNA per 16 nmole of liposome delivered to about  $10^6$  cells, and even more preferably about 2.0 g of DNA per 16 nmol of liposome delivered to about  $10^6$  cells. Preferably, a liposome is between about 100 and 500 nm, more preferably between 30 about 150 and 450 nm, and even more preferably between about 200 and 400 nm in diameter.

Suitable liposomes for use in the present invention include those liposomes standardly used in, for example, gene delivery methods known to those of skill in the art. More preferred liposomes include liposomes having a polycationic lipid composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol.

5      Optionally, a liposome comprises a compound capable of targeting the liposome to a particular cell type, such as a cell-specific ligand exposed on the outer surface of the liposome.

Complexing a liposome with a reagent such as an antisense oligonucleotide or

10     ribozyme can be achieved using methods which are standard in the art (see, for example, U.S. Patent 5,705,151). Preferably, from about 0.1 $\mu$ g to about 10  $\mu$ g of polynucleotide is combined with about 8 nmol of liposomes, more preferably from about 0.5  $\mu$ g to about 5  $\mu$ g of polynucleotides are combined with about 8 nmol liposomes, and even more preferably about 1.0  $\mu$ g of polynucleotides is combined

15     with about 8 nmol liposomes.

In another embodiment, antibodies can be delivered to specific tissues *in vivo* using receptor-mediated targeted delivery. Receptor-mediated DNA delivery techniques are taught in, for example, Findeis *et al.* *Trends in Biotechnol.* 11, 202-05 (1993); Chiou *et al.*, *GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER* (J.A. Wolff, ed.) (1994); Wu & Wu, *J. Biol. Chem.* 263, 621-24 (1988); Wu *et al.*, *J. Biol. Chem.* 269, 542-46 (1994); Zenke *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 87, 3655-59 (1990); Wu *et al.*, *J. Biol. Chem.* 266, 338-42 (1991).

Determination of a Therapeutically Effective Dose

The determination of a therapeutically effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of 5 active ingredient which increases or decreases DESC1-like serine protease activity relative to the DESC1-like serine protease activity which occurs in the absence of the therapeutically effective dose.

For any compound, the therapeutically effective dose can be estimated initially either 10 in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

15 Therapeutic efficacy and toxicity, e.g., ED<sub>50</sub> (the dose therapeutically effective in 50% of the population) and LD<sub>50</sub> (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD<sub>50</sub>/ED<sub>50</sub>.

20 Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little 25 or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

30 The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors which can be taken into account include the severity of the disease state, general

health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.

5

10

15

20

25

30

Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either *ex vivo* or *in vivo* using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun," and DEAE- or calcium phosphate-mediated transfection.

Effective *in vivo* dosages of an antibody are in the range of about 5  $\mu$ g to about 50  $\mu$ g/kg, about 50  $\mu$ g to about 5 mg/kg, about 100  $\mu$ g to about 500  $\mu$ g/kg of patient body weight, and about 200 to about 250  $\mu$ g/kg of patient body weight. For administration of polynucleotides encoding single-chain antibodies, effective *in vivo* dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg, about 1  $\mu$ g to about 2 mg, about 5  $\mu$ g to about 500  $\mu$ g, and about 20  $\mu$ g to about 100  $\mu$ g of DNA.

If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides which express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above.

5 Preferably, a reagent reduces expression of a DESC1-like serine protease gene or the activity of a DESC1-like serine protease polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of expression of a DESC1-like serine protease gene or the activity of a DESC1-like serine protease polypeptide can be assessed using methods well known in the art, such as hybridization of nucleotide probes to DESC1-like serine protease-specific mRNA, quantitative RT-PCR, immunologic detection of a DESC1-like serine protease polypeptide, or measurement of DESC1-like serine protease activity.

10

15 In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, 20 one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

25 Any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

Diagnostic Methods

30 Human DESC1-like serine protease also can be used in diagnostic assays for detecting diseases and abnormalities or susceptibility to diseases and abnormalities related to the

presence of mutations in the nucleic acid sequences which encode the enzyme. For example, differences can be determined between the cDNA or genomic sequence encoding DESC1-like serine protease in individuals afflicted with a disease and in normal individuals. If a mutation is observed in some or all of the afflicted 5 individuals but not in normal individuals, then the mutation is likely to be the causative agent of the disease.

Sequence differences between a reference gene and a gene having mutations can be revealed by the direct DNA sequencing method. In addition, cloned DNA segments 10 can be employed as probes to detect specific DNA segments. The sensitivity of this method is greatly enhanced when combined with PCR. For example, a sequencing primer can be used with a double-stranded PCR product or a single-stranded template molecule generated by a modified PCR. The sequence determination is performed by conventional procedures using radiolabeled nucleotides or by automatic sequencing 15 procedures using fluorescent tags.

Genetic testing based on DNA sequence differences can be carried out by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized, for 20 example, by high resolution gel electrophoresis. DNA fragments of different sequences can be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (see, e.g., Myers *et al.*, *Science* 230, 1242, 1985). Sequence changes at specific locations can also be 25 revealed by nuclease protection assays, such as RNase and S 1 protection or the chemical cleavage method (e.g., Cotton *et al.*, *Proc. Natl. Acad. Sci. USA* 85, 4397-4401, 1985). Thus, the detection of a specific DNA sequence can be performed by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes and Southern blotting of genomic DNA. 30 In addition to direct methods such as gel-electrophoresis and DNA sequencing, mutations can also be detected by *in situ* analysis.

Altered levels of a DESC1-like serine protease also can be detected in various tissues. Assays used to detect levels of the receptor polypeptides in a body sample, such as blood or a tissue biopsy, derived from a host are well known to those of skill in the art 5 and include radioimmunoassays, competitive binding assays, Western blot analysis, and ELISA assays.

All patents and patent applications cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. 10 A more complete understanding can be obtained by reference to the following specific examples which are provided for purposes of illustration only and are not intended to limit the scope of the invention.

EXAMPLE 1*Detection of DESC1-like serine protease activity*

5 The polynucleotide of SEQ ID NO: 6 is inserted into the expression vector pCEV4 and the expression vector pCEV4-DESC1-like serine protease polypeptide obtained is transfected into human embryonic kidney 293 cells.

10 Protease activity of cellular extracts from the transfected cells are measured using thiobenzylester substrates, as described in U.S. Patent 5,500,344. For monitoring enzyme activities from granules and column fractions, assays are performed at room temperature using 0.5 mM 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) (Sigma) to detect the HSBzl leaving group ( $\epsilon_{410} = 13600 \text{ M}^{-1} \text{ cm}^{-1}$ ).

15 Furthermore, BLT-esterase activity is estimated using a microtiter assay (Green and Shaw, *Anal. Biochem.* 93, 223-226, 1979). Briefly, 50  $\mu\text{l}$  of sample is added to 100  $\mu\text{l}$  of 1 mM DTNB, made up in 10 mM HEPES, 1 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , pH 7.2. The reaction is initiated by the addition of 50  $\mu\text{l}$  of BLT (Sigma) to give a final concentration of 500  $\mu\text{M}$ . For Metase determinations, 50  $\mu\text{l}$  of dilutions of the 20 sample in 0.1 M HEPES, 0.05 M  $\text{CaCl}_2$ , pH 7.5, are added to 100  $\mu\text{l}$  of 1 mM DTNB, and the reaction is initiated by the addition of 50  $\mu\text{l}$  of Boc-Ala-Ala-Met-S Benzyl (Bzl) to give a final concentration of 150  $\mu\text{M}$ . The duration of the assay depends on 25 color development, the rate of which is measured (O.D.<sub>410</sub>) on a Dynatech MR 5000 microplate reader. Controls of sample and DTNB alone or DTNB and substrate alone are run.

30 Additionally, peptide thiobenzyl ester substrates are used to measure protease activities. The chymase substrate Suc-Phe-Leu-Phe-SBzl is purchased from BACHEM Bioscience Inc., Philadelphia, Pa. Z-Arg-SBzl (the tryptase substrate, Kam *et al.*, *J. Biol. Chem.* 262, 3444-3451, 1987); Boc-Ala-Ala-AA-SBzl (AA=Asp, Met, Leu, Nle, or Ser), and Suc-Ala-Ala-Met-SBzl (Odake *et al.*, *Biochemistry* 30, 2217-

2227, 1991); Harper *et al.*, *Biochemistry* 23, 2995-3002, 1984) are synthesized previously. Boc-Ala-Ala-Asp-SBzl is the substrate for Asp-ase and peptide thiobenzyl esters containing Met, Leu or Nle are substrates for Met-ase SP. Assays are performed at room temperature in 0.1 M, HEPES buffer, pH 7.5, containing 0.01  
5 M CaCl<sub>2</sub> and 8% Me<sub>2</sub>O using 0.34 mM 4,4'-dithiodipyridine (Aldrich Chemical Co., Milwaukee, Wis.) to detect HSBzl leaving group that reacts with 4,4'-dithiodipyridine to release thiopyridone (324=19800 M<sup>-1</sup> cm<sup>-1</sup>, Grasetti and Murray, *Arch. Biochem. Biophys.* 119, 41-49, 1967). The initial rates are measured at 324 nm using a Beckman 35 spectrophotometer when 10-25 µl of an enzyme stock solution is  
10 added to a cuvette containing 2.0 ml of buffer, 150 µl of 4,4'-dithiodipyridine, and 25 µl of substrate. The same volume of substrate and 4,4'-dithiodipyridine are added to the reference cell in order to compensate for the background hydrolysis rate of the substrates. Initial rates are measured in duplicate for each substrate concentration and are averaged in each case. Substrate concentrations are 100-133 µM. The DESC1-like  
15 activity of the polypeptide of SEQ ID NO: 2 is shown.

## EXAMPLE 2

### *Expression of recombinant human DESC1-like serine protease*

20 The *Pichia pastoris* expression vector pPICZB (Invitrogen, San Diego, CA) is used to produce large quantities of recombinant human serine protease DESC1serine protease DESC1 polypeptides in yeast. The DESC1-like serine protease-encoding DNA sequence is derived from SEQ ID NO:6. Before insertion into vector pPICZB, the  
25 DNA sequence is modified by well known methods in such a way that it contains at its 5'-end an initiation codon and at its 3'-end an enterokinase cleavage site, a His6 reporter tag and a termination codon. Moreover, at both termini recognition sequences for restriction endonucleases are added and after digestion of the multiple cloning site of pPICZ B with the corresponding restriction enzymes the modified DNA sequence is  
30 ligated into pPICZB. This expression vector is designed for inducible expression in

*Pichia pastoris*, driven by a yeast promoter. The resulting pPICZ/md-His6 vector is used to transform the yeast

5 The yeast is cultivated under usual conditions in 5 liter shake flasks and the recombinantly produced protein isolated from the culture by affinity chromatography (Ni-NTA-Resin) in the presence of 8 M urea. The bound polypeptide is eluted with buffer, pH 3.5, and neutralized. Separation of the polypeptide from the His6 reporter tag is accomplished by site-specific proteolysis using enterokinase (Invitrogen, San Diego, CA) according to manufacturer's instructions. Purified human DESC1-like 10 serine protease polypeptide is obtained.

### EXAMPLE 3

#### *Identification of test compounds that bind to DESC1-like serine protease polypeptides*

15 Purified DESC1-like serine protease polypeptides comprising a glutathione-S-transferase protein and absorbed onto glutathione-derivatized wells of 96-well microtiter plates are contacted with test compounds from a small molecule library at pH 7.0 in a physiological buffer solution. DESC1-like serine protease polypeptides 20 comprise the amino acid sequence shown in SEQ ID NO:2. The test compounds comprise a fluorescent tag. The samples are incubated for 5 minutes to one hour. Control samples are incubated in the absence of a test compound.

25 The buffer solution containing the test compounds is washed from the wells. Binding of a test compound to a DESC1-like serine protease polypeptide is detected by fluorescence measurements of the contents of the wells. A test compound which increases the fluorescence in a well by at least 15% relative to fluorescence of a well in which a test compound is not incubated is identified as a compound which binds to a DESC1-like serine protease polypeptide.

**EXAMPLE 4**

*Identification of a test compound which decreases DESC1-like serine protease gene expression*

5 A test compound is administered to a culture of human cells transfected with a DESC1-like serine protease expression construct and incubated at 37 °C for 10 to 45 minutes. A culture of the same type of cells which have not been transfected is incubated for the same time without the test compound to provide a negative control.

10 RNA is isolated from the two cultures as described in Chirgwin *et al.*, *Biochem. 18*, 5294-99, 1979). Northern blots are prepared using 20 to 30 µg total RNA and hybridized with a <sup>32</sup>P-labeled DESC1-like serine protease-specific probe at 65 °C in Express-hyb (CLONTECH). The probe comprises at least 11 contiguous nucleotides selected from the complement of SEQ ID NO:6. A test compound which decreases 15 the DESC1-like serine protease-specific signal relative to the signal obtained in the absence of the test compound is identified as an inhibitor of DESC1-like serine protease gene expression.

**EXAMPLE 5**

20 *Treatment of a breast tumor with a reagent which specifically binds to a DESC1-like serine protease gene product*

Synthesis of antisense DESC1-like serine protease oligonucleotides comprising at 25 least 11 contiguous nucleotides selected from the complement of SEQ ID NO:6 is performed on a Pharmacia Gene Assembler series synthesizer using the phosphoramidite procedure (Uhlmann *et al.*, *Chem. Rev. 90*, 534-83, 1990). Following assembly and deprotection, oligonucleotides are ethanol-precipitated twice, dried, and suspended in phosphate-buffered saline (PBS) at the desired concentration. Purity of these oligonucleotides is tested by capillary gel electrophoreses and ion 30 exchange HPLC. Endotoxin levels in the oligonucleotide preparation are determined

- 59 -

using the *Limulus Amebocyte Assay* (Bang, *Biol. Bull. (Woods Hole, Mass.)* 105, 361-362, 1953).

The antisense oligonucleotides are administered directly to a patient's breast tumor.

- 5 The size of the patient's breast tumor is decreased.

CLAIMS

1. An isolated polynucleotide encoding a DESC1-like serine protease polypeptide and being selected from the group consisting of:
  - 5 a) a polynucleotide encoding a DESC1-like serine protease polypeptide comprising an amino acid sequence selected from the group consisting of:  
amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO: 2; and  
the amino acid sequence shown in SEQ ID NO: 2.
  - b) a polynucleotide comprising the sequence of SEQ ID NO: 6;
  - c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b);
  - d) a polynucleotide the sequence of which deviates from the polynucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code; and
  - e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a to (d)).
- 20 2. An expression vector containing any polynucleotide of claim 1.
3. A host cell containing the expression vector of claim 2.
4. A substantially purified DESC1-like serine protease polypeptide encoded by a polynucleotide of claim 1.
- 25 5. A method for producing a DESC1-like serine protease polypeptide, wherein the method comprises the following steps:
  - a) culturing the host cell of claim 3 under conditions suitable for the expression of the DESC1-like serine protease polypeptide; and

- b) recovering the DESC1-like serine protease polypeptide from the host cell culture.

6. A method for detection of a polynucleotide encoding a DESC1-like serine protease polypeptide in a biological sample comprising the following steps:

- 5 a) hybridizing any polynucleotide of claim 1 to a nucleic acid material of a biological sample, thereby forming a hybridization complex; and
- b) detecting said hybridization complex.

10 7. The method of claim 6, wherein before hybridization, the nucleic acid material of the biological sample is amplified.

8. A method for the detection of a polynucleotide of claim 1 or a DESC1-like serine protease polypeptide of claim 4 comprising the steps of:

15 contacting a biological sample with a reagent which specifically interacts with the polynucleotide or the DESC1-like serine protease polypeptide.

9. A diagnostic kit for conducting the method of any one of claims 6 to 8.

20 10. A method of screening for agents which decrease the activity of a DESC1-like serine protease, comprising the steps of:  
contacting a test compound with any DESC1-like serine protease polypeptide encoded by any polynucleotide of claim 1;  
detecting binding of the test compound to the DESC1-like serine protease polypeptide, wherein a test compound which binds to the polypeptide is  
25 identified as a potential therapeutic agent for decreasing the activity of a DESC1-like serine protease.

11. A method of screening for agents which regulate the activity of a DESC1-like serine protease, comprising the steps of:

30

contacting a test compound with a DESC1-like serine protease polypeptide encoded by any polynucleotide of claim 1; and

detecting a DESC1-like serine protease activity of the polypeptide, wherein a test compound which increases the DESC1-like serine protease activity is identified as a potential therapeutic agent for increasing the activity of the DESC1-like serine protease, and wherein a test compound which decreases the DESC1-like serine protease activity of the polypeptide is identified as a potential therapeutic agent for decreasing the activity of the DESC1-like serine protease.

10

12. A method of screening for agents which decrease the activity of a DESC1-like serine protease, comprising the steps of:

contacting a test compound with any polynucleotide of claim 1 and detecting binding of the test compound to the polynucleotide, wherein a test compound which binds to the polynucleotide is identified as a potential therapeutic agent for decreasing the activity of DESC1-like serine protease.

15

13. A method of reducing the activity of DESC1-like serine protease, comprising the steps of:

contacting a cell with a reagent which specifically binds to any polynucleotide of claim 1 or any DESC1-like serine protease polypeptide of claim 4, whereby the activity of DESC1-like serine protease is reduced.

20

14. A reagent that modulates the activity of a DESC1-like serine protease polypeptide or a polynucleotide wherein said reagent is identified by the method of any of the claim 10 to 12.

25

15. A pharmaceutical composition, comprising:

the expression vector of claim 2 or the reagent of claim 14 and a pharmaceutically acceptable carrier.

30

16. Use of the pharmaceutical composition of claim 15 for modulating the activity of a DESCl-like serine protease in a disease.
17. Use of claim 16 wherein the disease is cancer, chronic obstructive pulmonary disease (COPD), cardiovascular, peripheral or central nervous system disease.
18. A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
- 10 19. The cDNA of claim 18 which comprises SEQ ID NO:6.
20. The cDNA of claim 18 which consists of SEQ ID NO: 6.
- 15 21. An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
22. The expression vector of claim 21 wherein the polynucleotide consists of SEQ ID NO: 6.
- 20 23. A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
24. The host cell of claim 23 wherein the polynucleotide consists of SEQ ID NO: 6.
- 25 25. A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.
26. The purified polypeptide of claim 25 which consists of the amino acid sequence shown in SEQ ID NO:2.

27. A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO:2.
28. A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:
  - 5 culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed; and
  - isолating the polypeptide.
- 10 29. The method of claim 28 wherein the expression vector comprises SEQ ID NO: 6.
30. A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:
  - 15 hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO: 6 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
  - detecting the hybridization complex.
- 20 31. The method of claim 30 further comprising the step of amplifying the nucleic acid material before the step of hybridizing.
32. A kit for detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising:
  - 25 a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO: 6; and
  - instructions for the method of claim 30.
33. A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising the steps of:
  - 30 contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex; and

detecting the reagent-polypeptide complex.

34. The method of claim 33 wherein the reagent is an antibody.
- 5 35. A kit for detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, comprising:  
an antibody which specifically binds to the polypeptide; and  
instructions for the method of claim 33.
- 10 36. A method of screening for agents which can modulate the activity of a human DESC1-like serine protease, comprising the steps of:  
contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:2 and (2) the amino acid sequence shown in SEQ ID NO:2; and  
detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the human DESC1-like serine protease.
- 20 37. The method of claim 36 wherein the step of contacting is in a cell.
38. The method of claim 36 wherein the cell is *in vitro*.
39. The method of claim 36 wherein the step of contacting is in a cell-free system.
- 25 40. The method of claim 36 wherein the polypeptide comprises a detectable label.
41. The method of claim 36 wherein the test compound comprises a detectable label.

42. The method of claim 36 wherein the test compound displaces a labeled ligand which is bound to the polypeptide.

43. The method of claim 36 wherein the polypeptide is bound to a solid support.

5

44. The method of claim 36 wherein the test compound is bound to a solid support.

10

45. A method of screening for agents which modulate an activity of a human DESC1-like serine protease, comprising the steps of:  
contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 50% identical to the amino acid sequence shown in SEQ ID NO:2 and (2) the amino acid sequence shown in SEQ ID NO:2; and  
15 detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human DESC1-like serine protease, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential agent for decreasing the activity of the human DESC1-like serine protease.

20

46. The method of claim 45 wherein the step of contacting is in a cell.

47. The method of claim 45 wherein the cell is *in vitro*.

25

48. The method of claim 45 wherein the step of contacting is in a cell-free system.

49. A method of screening for agents which modulate an activity of a human DESC1-like serine protease, comprising the steps of:  
30 contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO: 6; and

detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human DESC1-like serine protease.

5        50. The method of claim 49 wherein the product is a polypeptide.

10      51. The method of claim 49 wherein the product is RNA.

15      52. A method of reducing activity of a human DESC1-like serine protease, comprising the step of: contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 6, whereby the activity of a human DESC1-like serine protease is reduced.

20      53. The method of claim 52 wherein the product is a polypeptide.

25      54. The method of claim 53 wherein the reagent is an antibody.

55. The method of claim 52 wherein the product is RNA.

56. The method of claim 55 wherein the reagent is an antisense oligonucleotide.

57. The method of claim 56 wherein the reagent is a ribozyme.

25      58. The method of claim 52 wherein the cell is *in vitro*.

59. The method of claim 52 wherein the cell is *in vivo*.

30      60. A pharmaceutical composition, comprising:

a reagent which specifically binds to a polypeptid comprising the amino acid sequence shown in SEQ ID NO:2; and a pharmaceutically acceptable carrier.

5        61. The pharmaceutical composition of claim 60 wherein the reagent is an antibody.

10        62. A pharmaceutical composition, comprising:  
              a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 6; and  
              a pharmaceutically acceptable carrier.

15        63. The pharmaceutical composition of claim 62 wherein the reagent is a ribozyme.

20        64. The pharmaceutical composition of claim 62 wherein the reagent is an antisense oligonucleotide.

25        65. The pharmaceutical composition of claim 62 wherein the reagent is an antibody.

66. A pharmaceutical composition, comprising:  
              an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2; and  
              a pharmaceutically acceptable carrier.

30        67. The pharmaceutical composition of claim 66 wherein the expression vector comprises SEQ ID NO: 6.

68. A method of treating a DESC1-like serine protease dysfunction related disease, wherein the disease is selected from cancer, chronic obstructive

5 pulmonary disease (COPD), cardiovascular, peripheral or central nervous system disease, comprising the step of: administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human DESC1-like serine protease, whereby symptoms of the DESC1-like serine protease dysfunction related disease are ameliorated.

10 69. The method of claim 68 wherein the reagent is identified by the method of claim 36.

15 70. The method of claim 68 wherein the reagent is identified by the method of claim 45.

71. The method of claim 68 wherein the reagent is identified by the method of claim 49.

Fig. 1

atgaagatga tcaaggctct agcagatgtc tgtccagagg  
aagatggtgt gaaagttagat gtcattatgg tggccagtt  
cccctctact gaacaaaggg cagtaagaga gaagaaaatc  
caaagcatct taaatcagaa gataaggaat ttaagagcct  
tgccaataaaa tgcctcatca gttcaagtta atgcaatgag  
ctcatcaaca ggggagttaa ctgtccaagc aagttgtgg  
aaacgagttg ttccattaaa cgtcaacaga atagcatctg  
gagtcattgc acccaaggcg gcctggcctt ggcaagcttc  
ccttcagtt gataacatcc atcagtgtgg ggccaccttg  
attagtaaca catggcttgt cactgcagca cactgcttc  
agaagtataa aaatccacat caatggactg tttagtttgg  
aacaaaaatc aaccctccct taatgaaaag aaatgtcaga  
agatttatta tccatgagaa gtaccgctct gcagcaagag  
agtacgacat tgctgttgtg caggtctctt ccagagtcac  
ctttcggat gacatacgcc agatttgtt gccagaagcc  
tctgcacccct tccaacccaa tttgactgtc cacatcacag  
gatttggagc actttactat ggtggggat cccaaaatga  
tctccgagaa gccagagtga aaatcataag tgatgatgtc  
tgcaagcaac cacaggtgtt tggcaatgtat ataaaacctg  
gaatgttctg tgccggat atggaaggaa tttatgatgc  
ctgcaggggt gattctgggg gaccttttagt cacaagggat  
ctgaaagata cgtggtatct cattggaatt gtaagctggg  
gagataactg tggtaaaaag gacaaggctg gagtctacac  
acaagtgtact tattaccgaa actggattgc ttcaaaaaca  
ggcatctaa **TTCACGATAA AAGTTAAACA AAGAAAGCTG**  
**TATGCAGGTC ATATATGCAT GAGAATTCAA CTATTTAGTG**  
**GGTGTAGTAC AACAAAGTGA TATTAAATTAA CTGGATCTAG**  
**TAACATGAAA CACACAACGT AAGTTATTAA GAATCACTTT**  
**AATCAACCAA TAATCCTTAG CCAATTAA**

- 2/10 -

Fig. 2

MKMIKALADV CPEEDGVKVD VIMVFQFPST EQRAVREKKI QSILNQKIRN LRALPINASS  
VQVNAMSSST GELTVQASC G KRVVPLNVNR IASGVIAPKA AWPWQASLQY DNIHQCGATL  
ISNTWLVTA HCFQKYKNPH QWTVSFGTKI NPPLMKRNVR RFIIHDKYRS AAREYDIAVV  
QVSSRVTFS D DIRQICLPEA SASFQPNLTV HITGFGALYY GGESQNDLRE ARVKIISDDV  
CKQPQVYGN D IKPGMFCAGY MEGIYDACRG DSGGPLVTRD LKDTWYLIGI VSWGDNCGQK  
DKPGVYTQVT YYRNWIASKT GI

- 3/10 -

Fig. 3

MYRPDVVRARKRVCWEPWVIGLVIFISLIVLAVCIGLTWHYVRYNQKKTYNYYSTLSPTTDKLYAEFG  
REASNNFTEMSQRLESMVKNAPYKSPLREFVKSQVIKFSQQKHGVLAHMLLICRFHSTEDPETVDKI  
VQLVLHEKLQDAVGPPKVDPHSVKIKKINKTETDSYLNHCCGTRRSKTLGQSLRIVGGTEVEEGEWPW  
QASLQWDGSHRCGATLINAATWLVSAAHCFTTYKNPARWTASFGVTIKPSKMKRLRRIIVHKKYKHP  
HDYDISLAELSSPVPTNAHRVCLPDASYEFQPGDVMFVTGFGALKNDGYSQNHRLRQAQVTLIDATT  
CNEPQAYNDAITPRMLCAGSLEGKTDACQGDGGPLVSSDARDIWYLAGIVSWGDECAPNPKPGVYTR  
VTALRDWITSKTGI

- 4/10 -

**Fig. 4**

IvGGreaqpgsfgsPwqvslqvrsgggsrkhfCGGsLisenwVLAAH  
CvsgaasapassvrVSlsvrlGehnlslteqkfdvkktiivHpny  
npdtldngaYdnDiALLkLkspgv

- 5/10 -

**Fig. 5**

gtgagctggg gagataactg tggtaaaaag gacaaggcctg  
gagtctacac acaagtgact tattaccgaa actggattgc  
ttcaaaaaca ggcatctaat tcacaataaa agttaaacaaaaaaa

- 6/10 -

Fig. 6

atgaagatga	tcaaggctct	agcagatgtc	tgtccagagg
aagatggtgt	gaaagtagat	gtcattatgg	tgttccagtt
cccctctact	gaacaaaggg	cagtaagaga	gaagaaaatc
caaagcatct	taaatcagaa	gataaggaat	ttaagagcct
tgccaataaa	tgcctcatca	gttcaagtta	atgcaatgag
ctcatcaaca	ggggagttaa	ctgtccaagc	aagttgtggt
aaacgagttg	ttccatttaaa	cgtcaacaga	atagcatctg
gagtcattgc	acccaaggcg	gcctggcctt	ggcaagcttc
ccttcagtat	gataacatcc	atcagtgtgg	ggccaccttg
attagtaaca	catggcttgt	cactgcagca	cactgcttcc
agaagtataa	aaatccacat	caatggactg	ttagtttgg
aacaaaaatc	aaccctccct	taatgaaaag	aatgtcaga
agatttatta	tccatgagaa	gtaccgctct	gcagcaagag
agtacgacat	tgctgttgtg	caggtctctt	ccagagtcac
cttttcggat	gacatacgcc	agatttgttt	gccagaagcc
tctgcacccct	tccaaaccaaa	tttgaactgtc	cacatcacag
gattttggagc	actttactat	ggtggggaat	cccaaaatga
tctccgagaa	gccagagtga	aaatcataag	tgatgatgtc
tgcaagcaac	cacaggtgta	tggcaatgat	ataaaaacctg
gaatgttctg	tgccggatat	atggaaggaa	tttatgatgc
ctgcagggggt	gattctgggg	gacctttagt	cacaaggat
ctgaaaagata	cgtggtatct	cattggaatt	gtaagctggg
gagataactg	tggtcaaaag	gacaagcctg	gagtctacac
acaagtgact	tattaccgaa	actggattgc	ttcaaaaaca
<u>ggcatctaa</u>			

- 7/10 -

FIG. 7

BLASTP - Query = 152\_ext(TR1; Hit = trembl|AF064819|AF064819\_1  
 This hit is scoring at : 7e-84 (expectation value)  
 Alignment length (overlap) : 313  
 Identities : 46 %  
 Scoring matrix : BLOSUM62 (used to infer consensus pattern)  
 Database searched : nrdb

Q: 13 EEDGVKVDVIMVFQFPSTEQRKKIQSILNQKIRNLRALP-INASSVQYNA  
 MSSSTG  
 ::.GV ::::: F STE. :: :K :Q :L :K :::: P ::. SV ::::: ::.  
 H: 110 QKHGVLAHMLLICRFHSTDPEYDKIVQLVHLKQLDAVGPPKVDPHSWKIKKINKTET  
 ELTVQASCG-KRVTPLNVN-RIASGVIAPKAAWPWQASLQYDNIHQCGATLISNTWLVTA  
 ::.CG :R .L. : RI .. G. :::: WPWQASLQ:D. H:CGATL: TWLV: A  
 DSYLNHCCGTRRSKTLGQSLRIVGGTEVEEGWPWQASLQWDGSHRCGATLINA  
 TWLV:SA  
 AHCFQKYYKNPHQWTVSFGTKINPPLMKRNVRRFIHEKYRSAAREYDIAVVQVSSRVTFS  
 AHCF..YKNP:WT.SFG..I.P. MKR.:RR.I:HEKY: :::YDI: :::SS V.:  
 AHCFYYKYNPARWTASFGVTKPSKMKRGLRRIIVHEKYKHPHSYDYSISLSSPVPYT  
 TRYPSIN HIS  
 DDIRQICLPEASASFOPNLTVTHITGFGALYYGGESQNDLREARVKIISDDVCKQPOVYGN  
 :::CLP:AS .FOP. :: :TGFGAL .G SQN.LR: A:V. ::I. ::C. :PQ.Y.:  
 NAVHRVCLPDASEYFQPGDVMFTGFGALKNDGYSQNLIRQAQVTLIDATTNCNEQAYND  
 DIKPGMFCAGYMEGIYDACPQD8GGPLVTRDLKDTWYLIGIVSGDNCGQDKPGVYIQQV  
 I.P.M.CAG :EG DAC :GDGGGPLV:D.D.WYL.GIVSWGD.C. :::KPGVYI:V  
 AITPRMLCAGSLEGKTDACQD8GGPLVSSDARDIWLLAGIVSGDCEAKPNKPGVYIIRV  
 TRYPSIN \_SER  
 TYYRNWIAASKTGI  
 T.R:WI.SKIGI  
 TALRDWITSKIGI

322

422

- 8/10 -

FIG. 8

BLOCKS  
Prosite search results

Access#	From->To	Name	Doc#
PS000134	127->133	TRYPSIN_HIS	PDOC00124
PS000135	266->278	TRYPSIN_SER	PDOC00124

FIG. 9

AC#	Description	Strength
BL01253H	Type I fibronectin domain proteins.	1765 (SEQ ID NO: 6)
AA# 284	WYLIIGIVSWGDNCQDKPGVITqVTYYRNWIask	1584 (SEQ ID NO: 6)
BL01253G	Type I fibronectin domain proteins.	1641 (SEQ ID NO: 7)
AA# 264	YDAGCrGDSGGPLVt	1429 (SEQ ID NO: 7)
BL00134A	Serine proteases, trypsin family, histidine P	1500 (SEQ ID NO: 7)
AA# 115	CGATLISNTWLVTAAHC	1424 (SEQ ID NO: 8)
BL00021B	Kringle domain proteins.	1419 (SEQ ID NO: 9)
AA# 115	CGATLISNTWLVTAAHC	1419 (SEQ ID NO: 9)
BL00021D	Kringle domain proteins.	1355 (SEQ ID NO: 10)
AA# 274	plvtrdLKDtwYLIGIVSWGDnCGQKDPKPGVTTqVTYYRNWI	1556 (SEQ ID NO: 10)
BL00495O	Apple domain proteins.	1341 (SEQ ID NO: 11)
AA# 293	GdnCGQKDpkPGVTTqVTYYRNWIaskTgi	1756 (SEQ ID NO: 11)
BL01253F	Type I fibronectin domain proteins.	1314 (SEQ ID NO: 12)
AA# 220	ggEsgnndlREArVkiisDdvCkqPqYYGnDlkPGMfCAG	1693 (SEQ ID NO: 12)
BL00134C	Serine proteases, trypsin family, histidine P	1245 (SEQ ID NO: 12)
AA# 302	PGVYTQVTTYYRNWI	1259 (SEQ ID NO: 13)
BL00495N	Apple domain proteins.	1945 (SEQ ID NO: 14)
AA# 257	AGYmEGlyDACrGDSGGPLVtrdLkdtwyligivs	1226 (SEQ ID NO: 14)
BL00134B	Serine proteases, trypsin family, histidine P	1289 (SEQ ID NO: 14)
AA# 265	DACRGDSSGGPLVTRDLDKDTWYLIG	1204 (SEQ ID NO: 15)

- 10/10 -

FIG. 10

HMMFFAM - alignment of 152\_ext\_TR1 against pfam|hmm|trypsin

Trypsin

This hit is scoring at : 273.6; Expect = 4.6e-86

Scoring matrix : BLOSUM62 (used to infer consensus pattern)

Q: 91 IASGVIAPKAAW-PWQASLQYDN-- IHQCCATLISNTWLVTAACFQK- YKNPHQWTV  
I. G A...::: PWQ. SLQ. : H CG. :LIS. .W.: TAAHC. . . . . V  
H: 1 IvgGreaqpgBfgSPwqyslqvrggggrkhfcGGSLisewVLTAAHCvsgqaaasapasSvrv

-----SFGT---KINPP-LMKRNVR-FIIEKYRSAARE-----YDIAVVQVSSR-V  
...G. .::... .K :V: : .I:H. .Y. . . : DIA::: .S V  
S1svr1GehnlsltgeqkfdvkktliiHpnypptldngaydnDiallklikspgv (SEQ ID NO: 4)

## SEQUENCE LISTING

<110> Bayer AG  
Bull, Christof

<120> REGULATION OF HUMAN DESC1-LIKE SERINE PROTEASE

<130> I10112 Foreign countries

<150> 60/218,832

<151> 2000-07-18

<160> 6

<170> PatentIn version 3.1

<210> 1

<211> 1147

<212> DNA

<213> Homo sapiens

<220>

<221> terminator

<222> (967)..(970)

<223>

<400> 1  
atgaagatga tcaaggctct agcagatgtc tgtccagagg aagatggtgt gaaagttagat 60  
gtcattatgg tggccatgtt cccctctact gaacaaaggc cagtaagaga gaagaaaatc 120  
caaaggcatct taaatcagaa gataaggaat ttaagggcct tgccaaataaa tgcctcatca 180  
gttcaagttt atgcaatggc ctcataaca ggggagttaa ctgtccaaagc aagttgttgt 240  
aaacgagttt ttccattttaa cgtcaacaga atagcatctg gagtccattgc acccaaggcg 300  
gcctggccctt ggcaagcttc ctttcgttat gataacatcc atcagtgtgg ggccacccctt 360  
attagtaaca catgggtttgtt cactgcagca cactgcttcc agaagtataa aaatccacat 420  
caatggactg ttagttttgg aacaaaaatc aaccctccct taatgaaaag aaatgtcaga 480  
agattttata tccatgagaa gtaccgctct gcagcaagag agtacgacat tgctgttgt 540  
caggttotctt ccagagtcac cttttagat gacatacgcc agatttgttt gccagaagcc 600  
totgcacatcc tccaaacaaa tttgactgtc cacatcacag gatggggagc actttactat 660  
ggggggaaat cccaaaatga tctccgagaa gccagagtga aaatcataag tgatgtgtc 720  
tgcacacac cacagggtgtt tggcaatgtat ataaaaacctg gaatgttgtc tgcggatata 780  
atggaaaggaa tttatgtatgc ctgcagggtt gatttgggg gaccttttagt cacaaggat 840  
ctgaaagata cgtggtatct cattggaaatt gtaagctggg gagataactg tggtaaaaag 900  
gacaaggctg gagtctacac acaagtgtact tattaccgaa actggattgc ttcaaaaaca 960  
ggcatataat tcaacgataaa agttaaacaa agaaagctgt atgcagggtca tatatgoatg 1020  
agaatccaaac tatttagtgg gtgttagtaca acaaagtgtat attaaattac tggatctagt 1080

aacatgaaac acacaacgta agttatTTAG aatcaCTTta atcaaccaat aatcCTTAGC 1140  
 caattta 1147

<210> 2  
 <211> 322  
 <212> PRT  
 <213> Homo sapiens

<400> 2

Met Lys Met Ile Lys Ala Leu Ala Asp Val Cys Pro Glu Glu Asp Gly  
 1 5 10 15

Val Lys Val Asp Val Ile Met Val Phe Gln Phe Pro Ser Thr Glu Gln  
 20 25 30

Arg Ala Val Arg Glu Lys Lys Ile Gln Ser Ile Leu Asn Gln Lys Ile  
 35 40 45

Arg Asn Leu Arg Ala Leu Pro Ile Asn Ala Ser Ser Val Gln Val Asn  
 50 55 60

Ala Met Ser Ser Thr Gly Glu Leu Thr Val Gln Ala Ser Cys Gly  
 65 70 75 80

Lys Arg Val Val Pro Leu Asn Val Asn Arg Ile Ala Ser Gly Val Ile  
 85 90 95

Ala Pro Lys Ala Ala Trp Pro Trp Gln Ala Ser Leu Gln Tyr Asp Asn  
 100 105 110

Ile His Gln Cys Gly Ala Thr Leu Ile Ser Asn Thr Trp Leu Val Thr  
 115 120 125

Ala Ala His Cys Phe Gln Lys Tyr Lys Asn Pro His Gln Trp Thr Val  
 130 135 140

Ser Phe Gly Thr Lys Ile Asn Pro Pro Leu Met Lys Arg Asn Val Arg  
 145 150 155 160

Arg Phe Ile Ile His Glu Lys Tyr Arg Ser Ala Ala Arg Glu Tyr Asp  
 165 170 175

Ile Ala Val Val Gln Val Ser Ser Arg Val Thr Phe Ser Asp Asp Ile  
 180 185 190

Arg Gln Ile Cys Leu Pro Glu Ala Ser Ala Ser Phe Gln Pro Asn Leu  
 195 200 205

Thr Val His Ile Thr Gly Phe Gly Ala Leu Tyr Tyr Gly Gly Glu Ser  
 210 215 220

Gln Asn Asp Leu Arg Glu Ala Arg Val Lys Ile Ile Ser Asp Asp Val  
 225 230 235 240

Cys Lys Gln Pro Gln Val Tyr Gly Asn Asp Ile Lys Pro Gly Met Phe  
 245 250 255

Cys Ala Gly Tyr Met Glu Gly Ile Tyr Asp Ala Cys Arg Gly Asp Ser  
 260 265 270

Gly Gly Pro Leu Val Thr Arg Asp Leu Lys Asp Thr Trp Tyr Leu Ile  
 275 280 285

Gly Ile Val Ser Trp Gly Asp Asn Cys Gly Gln Lys Asp Lys Pro Gly  
 290 295 300

Val Tyr Thr Gln Val Thr Tyr Tyr Arg Asn Trp Ile Ala Ser Lys Thr  
 305 310 315 320

Gly Ile

<210> 3  
 <211> 422  
 <212> PRT  
 <213> Homo sapiens

<400> 3

Met Tyr Arg Pro Asp Val Val Arg Ala Arg Lys Arg Val Cys Trp Glu  
 1 5 10 15

Pro Trp Val Ile Gly Leu Val Ile Phe Ile Ser Leu Ile Val Leu Ala  
 20 25 30

Val Cys Ile Gly Leu Thr Val His Tyr Val Arg Tyr Asn Gln Lys Lys  
 35 40 45

Thr Tyr Asn Tyr Tyr Ser Thr Leu Ser Phe Thr Thr Asp Lys Leu Tyr  
 50 55 60

Ala Glu Phe Gly Arg Glu Ala Ser Asn Asn Phe Thr Glu Met Ser Gln  
 65 70 75 80

Arg Leu Glu Ser Met Val Lys Asn Ala Phe Tyr Lys Ser Pro Leu Arg  
 85 90 95

Glu Glu Phe Val Lys Ser Gln Val Ile Lys Phe Ser Gln Gln Lys His  
 100 105 110

Gly Val Leu Ala His Met Leu Leu Ile Cys Arg Phe His Ser Thr Glu  
 115 120 125

Asp Pro Glu Thr Val Asp Lys Ile Val Gln Leu Val Leu His Glu Lys  
 130 135 140

Leu Gln Asp Ala Val Gly Pro Pro Lys Val Asp Pro His Ser Val Lys  
 145 150 155 160

Ile Lys Lys Ile Asn Lys Thr Glu Thr Asp Ser Tyr Leu Asn His Cys  
 165 170 175

Cys Gly Thr Arg Arg Ser Lys Thr Leu Gly Gln Ser Leu Arg Ile Val  
 180 185 190

Gly Gly Thr Glu Val Glu Glu Gly Glu Trp Pro Trp Gln Ala Ser Leu  
 195 200 205

Gln Trp Asp Gly Ser His Arg Cys Gly Ala Thr Leu Ile Asn Ala Thr  
 210 215 220

Trp Leu Val Ser Ala Ala His Cys Phe Thr Thr Tyr Lys Asn Pro Ala  
 225 230 235 240

Arg Trp Thr Ala Ser Phe Gly Val Thr Ile Lys Pro Ser Lys Met Lys  
 245 250 255

Arg Gly Leu Arg Arg Ile Ile Val His Glu Lys Tyr Lys His Pro Ser  
 260 265 270

His Asp Tyr Asp Ile Ser Leu Ala Glu Leu Ser Ser Pro Val Pro Tyr  
 275 280 285

Thr Asn Ala Val His Arg Val Cys Leu Pro Asp Ala Ser Tyr Glu Phe  
 290 295 300

Gln Pro Gly Asp Val Met Phe Val Thr Gly Phe Gly Ala Leu Lys Asn  
 305 310 315 320

Asp Gly Tyr Ser Gln Asn His Leu Arg Gln Ala Gln Val Thr Leu Ile  
 325 330 335

Asp Ala Thr Thr Cys Asn Glu Pro Gln Ala Tyr Asn Asp Ala Ile Thr

340

345

350

Pro Arg Met Leu Cys Ala Gly Ser Leu Glu Gly Lys Thr Asp Ala Cys  
355 360 365

Gln Gly Asp Ser Gly Gly Pro Leu Val Ser Ser Asp Ala Arg Asp Ile  
370 375 380

Trp Tyr Leu Ala Gly Ile Val Ser Trp Gly Asp Glu Cys Ala Lys Pro  
385 390 395 400

Asn Lys Pro Gly Val Tyr Thr Arg Val Thr Ala Leu Arg Asp Trp Ile  
405 410 415

Thr Ser Lys Thr Gly Ile  
420

<210> 4  
<211> 120  
<212> PRT  
<213> Homo sapiens

<400> 4

Ile Val Gly Gly Arg Glu Ala Gln Pro Gly Ser Phe Gly Ser Pro Trp  
1 5 10 15

Gln Val Ser Leu Gln Val Arg Ser Gly Gly Ser Arg Lys His Phe  
20 25 30

Cys Gly Gly Ser Leu Ile Ser Glu Asn Trp Val Leu Thr Ala Ala His  
35 40 45

Cys Val Ser Gly Ala Ala Ser Ala Pro Ala Ser Ser Val Arg Val Ser  
50 55 60

Leu Ser Val Arg Leu Gly Glu His Asn Leu Ser Leu Thr Glu Gly Thr  
65 70 75 80

Glu Gln Lys Phe Asp Val Lys Lys Thr Ile Ile Val His Pro Asn Tyr  
85 90 95

Asn Pro Asp Thr Leu Asp Asn Gly Ala Tyr Asp Asn Asp Ile Ala Leu  
100 105 110

Leu Lys Leu Lys Ser Pro Gly Val  
115 120

<210> 5

<211> 124  
<212> DNA  
<213> Homo sapiens

<400> 5  
gtgagctggg gagataactg tggtaaaaag gacaaggctg gagtctacac acaagtgact 60  
tattaccgaa actggattgc ttcaaaaaca ggcatcta at tcacaataaa agttaaacaa 120  
aaaaa 124

<210> 6  
<211> 969  
<212> DNA  
<213> Homo sapiens

<400> 6  
atgaagatga tcaaggctct agcagatgtc tgtccagagg aagatggtgt gaaagttagat 60  
gtcattatgg tgttccagtt cccctctact gaacaaaggg cagtaagaga gaagaaaatc 120  
caaagcatct taaatcagaa gataaggaat ttaagagcct tgccaataaa tgccctcatca 180  
gttcaagtta atgcaatgag ctcataaca ggggagttaa ctgtccaagc aagttgttgt 240  
aaacgagttg ttccattaaa cgtcaacaga atagcatctg gagtcattgc accaaaggcg 300  
gcctggcctt ggcaagcttc ctttcagtt gataacatcc atcagtgtgg ggccaccctg 360  
attagtaaca catggcttgc cactgcagca cactgcttcc agaagtataa aaatccacat 420  
caatggactg ttagtttgg aacaaaaatc aaccctccct taatgaaaag aaatgtcaga 480  
agatttatta tccatgagaa gtacogctct gcagcaagag agtacgacat tgctgttgt 540  
caggtctctt ccagagtcac ctttccggat gacatacgcc agatttgttt gccagaagcc 600  
tctgcacatct tccaaacaaa tttgactgtc cacatcacag gatttggagc actttactat 660  
ggtggggaat cccaaaaatga tctccgagaa gccagagtga aaatcataag tgatgtgtc 720  
tgcaagcaac cacaggtgta tggcaatgtat ataaaaacctg gaatgttctg tgccggatata 780  
atgaaaggaa tttatgtgc ctgcagggggt gattctgggg gaccttagt cacaaggat 840  
ctgaaagata cgtggtatct cattggaaatt gtaagctggg gagataactg tggtaaaaag 900  
gacaaggctg gagtctacac acaagtgact tattaccgaa actggattgc ttcaaaaaca 960  
ggcatctaa 969